Locations:
SearchAdvertisement
Cleveland Clinic-developed “compound 3” begins testing in preclinical Alzheimer’s model
Finding suggests need for multifront therapeutic approach
Targeting SBP to less than 140 mm Hg led to more acute cerebral ischemia and neurologic deterioration
Retrospective reports fuel cautious optimism for broader use
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Nonpharmacologic management improves QoL over 12 weeks
Safety is focus of pilot study in a high-risk population
Retrospective study fills evidence gap on therapy’s merits in older adults
Phase 1/2 clinical trial builds on encouraging pilot study
Exploring rates, drivers and implications of failed catheter removal
Largest study to date underscores mental status, etiology, epileptiform patterns
Advertisement
Advertisement